De novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 5, 2016, Pages 596-606

  Tikkanen, Jussi M ^a   Singer, Lianne G ^a   Kim, S Joseph ^a   Li, Yanhong ^a   Binnie, Matthew ^a   Chaparro, Cecilia ^a   Chow, Chung Wai ^a   Martinu, Tereza ^a   Azad, Sassan ^a   Keshavjee, Shaf ^a   Tinckam, Kathryn ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Bronchiolitis obliterans syndrome; Chronic lung allograft dysfunction; Donor specific antibodies; Lung transplantation

Indexed keywords

ALLOANTIBODY; AZATHIOPRINE; AZITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DE NOVO DONOR SPECIFIC ANTIBODY; EPITOPE; GLOBULIN; HLA ANTIBODY; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; AUTOIMMUNITY; CHRONIC LUNG ALLOGRAFT GYSFUNCTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EX VIVO STUDY; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LUNG GRAFT REJECTION; LUNG PERFUSION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURGICAL RISK; SURVIVAL RATE; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; ADVERSE EFFECTS; ALLOGRAFT; BRONCHIOLITIS OBLITERANS; COMPLICATION; DONOR; GRAFT REJECTION; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG; MIDDLE AGED; ONTARIO; PROPORTIONAL HAZARDS MODEL; SEX RATIO; STATISTICS AND NUMERICAL DATA;

ALLOGRAFTS; BRONCHIOLITIS OBLITERANS; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; ONTARIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; TISSUE DONORS;

EID: 84988904843     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201509-1857OC     Document Type: Article

References (38)

1. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant 2014;33:127-133.
2. Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Lund LH, Rahmel AO, et al.; International Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation. Thirtieth adult lung and heart-lung transplant report-2013; focus theme: age. J Heart Lung Transplant 2013;32:965-978.
3. Lachmann N, Todorova K, Schulze H, Schönemann C. Luminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion. Transfus Med Hemother 2013; 40:182-189.
4. Girnita AL, Duquesnoy R, Yousem SA, Iacono AT, Corcoran TE, Buzoianu M, Johnson B, Spichty KJ, Dauber JH, Burckart G, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005;5: 131-138.
5. Hadjiliadis D, Chaparro C, Reinsmoen NL, Gutierrez C, Singer LG, Steele MP, Waddell TK, Davis RD, Hutcheon MA, Palmer SM, et al. Pretransplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005;24: S249-S254.
6. Snyder LD, Wang Z, Chen DF, Reinsmoen NL, Finlen-Copeland CA, Davis WA, Zaas DW, Palmer SM. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest 2013;144:226-233.
7. Brugière O, Suberbielle C, Thabut G, Lhuillier E, Dauriat G, Metivier AC, Gautreau C, Charron D, Mal H, Parquin F, et al. Lung transplantation in patients with pretransplantation donor-specific antibodies detected by Luminex assay. Transplantation 2013;95:761-765.
8. Kim M, Townsend KR, Wood IG, Boukedes S, Guleria I, Gabardi S, El-Chemaly S, Camp PC, Chandraker AK, Milford EL, et al. Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates. Am J Respir Crit Care Med 2014;189:1234-1239.
9. Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013;95: 19-47.
10. Tinckam KJ, Keshavjee S, Chaparro C, Barth D, Azad S, Binnie M, Chow CW, de Perrot M, Pierre AF, Waddell TK, et al. Survival in sensitized lung transplant recipients with perioperative desensitization. Am J Transplant 2015;15:417-426.
11. Morrell MR, Pilewski JM, Gries CJ, Pipeling MR, Crespo MM, Ensor CR, Yousem SA, D'Cunha J, Shigemura N, Bermudez CA, et al. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant 2014;33: 1288-1294.
12. Safavi S, Robinson DR, Soresi S, Carby M, Smith JD. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2014;33:1273-1281.
13. Berry G, Burke M, Andersen C, Angelini A, Bruneval P, Calabrese F, Fishbein MC, Goddard M, Leone O, Maleszewski J, et al. Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant 2013;32: 14-21.
14. Everly MJ, Rebellato LM, Ozawa M, Briley KP, Catrou PG, Haisch CE, Terasaki PI. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010;89:962-967.
15. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donorspecific antibody kidney transplantation outcomes. Transplantation 2013;95:1113-1119.
16. Ginevri F, Nocera A, Comoli P, Innocente A, Cioni M, Parodi A, Fontana I, Magnasco A, Nocco A, Tagliamacco A, et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 2012;12:3355-3362.
17. Sapir-Pichhadze R, Tinckam K, Quach K, Logan AG, Laupacis A, John R, Beyene J, Kim SJ. HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study. Am J Transplant 2015;15:137-148.
18. Wiebe C, Pochinco D, Blydt-Hansen TD, Ho J, Birk PE, Karpinski M, Goldberg A, Storsley LJ, Gibson IW, Rush DN, et al. Class II HLA epitope matching: a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013;13:3114-3122.
19. Willicombe M, Brookes P, Sergeant R, Santos-Nunez E, Steggar C, Galliford J, McLean A, Cook TH, Cairns T, Roufosse C, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012;94:172-177.
20. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1qfixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011;91:342-347.
21. Tikkanen JM, Singer LG, Azad S, Binnie M, Chaparro C, Chow C, Cypel M, dePerrot M, Pierre A, Yasufuku K, et al. De novo DQ donorspecific antibodies are associated with chronic lung allograft dysfunction. J Heart Lung Transplant 2014;33:S98-S99.
22. Gebel HM, Bray RA. HLA antibody detection with solid phase assays: great expectations or expectations too great? Am J Transplant 2014; 14:1964-1975.
23. Konvalinka A, Tinckam K. Utility of HLA antibody testing in kidney transplantation. J Am Soc Nephrol 2015;26:1489-1502.
24. Archdeacon P, Chan M, Neuland C, Velidedeoglu E, Meyer J, Tracy L, Cavaille-Coll M, Bala S, Hernandez A, Albrecht R. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011;11: 896-906.
25. Tambur AR, Herrera ND, Haarberg KM, Cusick MF, Gordon RA, Leventhal JR, Friedewald JJ, Glotz D. Assessing antibody strength: comparison of MFI, C1q, and titer information. Am J Transplant 2015;15:2421-2430.
26. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21: 297-310.
27. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a timevarying covariate with an extended Kaplan-Meier estimator. Am Stat 2005;59:301-307.
28. Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, Savik K, Reinsmoen NL. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002;74:799-804.
29. Smith MA, Sundaresan S, Mohanakumar T, Trulock EP, Lynch JP, Phelan DL, Cooper JD, Patterson GA. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 1998;116:812-820.
30. Sundaresan S, Mohanakumar T, Smith MA, Trulock EP, Lynch J, Phelan D, Cooper JD, Patterson GA. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998;65:648-653.
31. Hachem RR, Yusen RD, Meyers BF, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010;29:973-980.
32. Bosanquet JP, Witt CA, Bemiss BC, Byers DE, Yusen RD, Patterson AG, Kreisel D, Mohanakumar T, Trulock EP, Hachem RR. The impact of pre-transplant allosensitization on outcomes after lung transplantation. J Heart Lung Transplant 2015;34: 1415-1422.
33. Tinckam K, Azad S, Barth D, Binnie M, Chaparro C, Chow CW, Cypel M, dePerrot M, Pierre A, Waddell T, et al. Improved survival with perioperative desensitization in lung transplant patients with donor specific antibodies (DSA). J Heart Lung Transplant 2013; 32:S75.
34. Hirai T, Furusawa M, Omoto K, Ishida H, Tanabe K. Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients. Transplantation 2014;98:443-450.
35. Tikkanen JM, Cypel M, Machuca TN, Azad S, Binnie M, Chow CW, Chaparro C, Hutcheon M, Yasufuku K, de Perrot M, et al. Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation. J Heart Lung Transplant 2015;34: 547-556.
36. Shin S, Kim YH, Choi BH, Choi JY, Jung JH, Cho HK, Han DJ. Longterm impact of human leukocyte antigen mismatches combined with expanded criteria donor on allograft outcomes in deceased donor kidney transplantation. Clin Transplant 2015;29:44-51.
37. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013;95:410-417.
38. Issa N, Cosio FG, Gloor JM, Sethi S, Dean PG, Moore SB, DeGoey S, Stegall MD. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008;86:681-685.